Oral immunization with attenuated Salmonella carrying a co-expression plasmid encoding the core and E2 proteins of hepatitis C virus capable of inducing cellular immune responses and neutralizing antibodies in mice

Vaccine

Volumn 29, Issue 20, 2011, Pages 3714-3723

  Cao, Jie ^a   Chen, Zhihui ^b   Ren, Yanli ^a   Luo, Yuan ^a   Cao, Mingmei ^a   Lu, Wei ^a   Zhao, Ping ^a   Qi, Zhongtian ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Core protein; Envelope proteins; Hepatitis C virus; Immune responses; Neutralizing antibodies; Salmonella; Vaccine

Indexed keywords

CORE PROTEIN; DNA VACCINE; HEPATITIS C VACCINE; NEUTRALIZING ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; ENHANCER REGION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; IMMUNIZATION; INFECTION PREVENTION; MOUSE; NONHUMAN; PLASMID; PRIORITY JOURNAL; PROMOTER REGION; SALMONELLA TYPHIMURIUM;

ADMINISTRATION, ORAL; ANIMALS; ANTIBODIES, NEUTRALIZING; CYTOMEGALOVIRUS; EPITOPES; GENETIC VECTORS; HEK293 CELLS; HEPACIVIRUS; HEPATITIS C; HEPATITIS C ANTIBODIES; HUMANS; IMMUNITY, CELLULAR; INTERFERON-GAMMA; INTERLEUKIN-4; MICE; MICE, INBRED BALB C; NEUTRALIZATION TESTS; PLASMIDS; PROMOTER REGIONS, GENETIC; SALMONELLA; T-LYMPHOCYTES, CYTOTOXIC; VIRAL CORE PROTEINS; VIRAL ENVELOPE PROTEINS; VIRAL HEPATITIS VACCINES;

EID: 79955087105     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.02.083     Document Type: Article

References (59)

1. Shepard C.W., Finelli L., Alter M.J. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005, 5(September (9)):558-567.
2. Seeff L.B. Natural history of chronic hepatitis C. Hepatology 2002, 36(November (5 Suppl. 1)):S35-S46.
3. Farci P., Purcell R.H. Clinical significance of hepatitis C virus genotypes and quasispecies. Semin Liver Dis 2000, 20(1):103-126.
4. Pawlotsky J.M. Hepatitis C virus population dynamics during infection. Curr Top Microbiol Immunol 2006, 299:261-284.
5. Pavio N., Lai M.M. The hepatitis C virus persistence: how to evade the immune system?. J Biosci 2003, 28(April (3)):287-304.
6. Rehermann B. Hepatitis C virus versus innate and adaptive immune responses: a tale of coevolution and coexistence. J Clin Invest 2009, 119(July (7)):1745-1754.
7. Ishii S., Koziel M.J. Immune responses during acute and chronic infection with hepatitis C virus. Clin Immunol 2008, 128(August (2)):133-147.
8. Thimme R., Neumann-Haefelin C., Boettler T., Blum H.E. Adaptive immune responses to hepatitis C virus: from viral immunobiology to a vaccine. Biol Chem 2008, 389(May (5)):457-467.
9. Bukh J., Purcell R.H., Miller R.H. Sequence analysis of the core gene of 14 hepatitis C virus genotypes. Proc Natl Acad Sci U S A 1994, 91(August (17)):8239-8243.
10. Jackson M., Smith B., Bevitt D.J., Steward M., Toms G.L., Bassendine M.F., et al. Comparison of cytotoxic T-lymphocyte responses to hepatitis C virus core protein in uninfected and infected individuals. J Med Virol 1999, 58(July (3)):239-246.
11. Wang Y.F., Brotman B., Andrus L., Prince A.M. Immune response to epitopes of hepatitis C virus (HCV) structural proteins in HCV-infected humans and chimpanzees. J Infect Dis 1996, 173(April (4)):808-821.
12. Shata M.T., Anthony D.D., Carlson N.L., Andrus L., Brotman B., Tricoche N., et al. Characterization of the immune response against hepatitis C infection in recovered, and chronically infected chimpanzees. J Viral Hepat 2002, 9(November (6)):400-410.
13. Thimme R., Bukh J., Spangenberg H.C., Wieland S., Pemberton J., Steiger C., et al. Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease. Proc Natl Acad Sci U S A 2002, 99(November (24)):15661-15668.
14. Elmowalid G.A., Qiao M., Jeong S.H., Borg B.B., Baumert T.F., Sapp R.K., et al. Immunization with hepatitis C virus-like particles results in control of hepatitis C virus infection in chimpanzees. Proc Natl Acad Sci U S A 2007, 104(May (20)):8427-8432.
15. Eisen-Vandervelde A.L., Waggoner S.N., Yao Z.Q., Cale E.M., Hahn C.S., Hahn Y.S. Hepatitis C virus core selectively suppresses interleukin-12 synthesis in human macrophages by interfering with AP-1 activation. J Biol Chem 2004, 279(October (42)):43479-43486.
16. Kimball P., Verbeke S., Shiffman M. HCV core protein augments cyclosporine immunosuppression. Transplant Proc 2005, 37(March (2)):652-653.
17. Yao Z.Q., Shata M.T., Tricoche N., Shan M.M., Brotman B., Pfahler W., et al. gC1qR expression in chimpanzees with resolved and chronic infection: potential role of HCV core/gC1qR-mediated T cell suppression in the outcome of HCV infection. Virology 2006, 346(March (2)):324-337.
18. Dolganiuc A., Chang S., Kodys K., Mandrekar P., Bakis G., Cormier M., et al. Hepatitis C virus (HCV) core protein-induced, monocyte-mediated mechanisms of reduced IFN-alpha and plasmacytoid dendritic cell loss in chronic HCV infection. J Immunol 2006, 177(November (10)):6758-6768.
19. Waggoner S.N., Hall C.H., Hahn Y.S. HCV core protein interaction with gC1q receptor inhibits Th1 differentiation of CD4+ T cells via suppression of dendritic cell IL-12 production. J Leukoc Biol 2007, 82(December (6)):1407-1419.
20. Liao X.L., Ren H., Zhao P., Zhu S.Y., Cao J., Chen Z.H., et al. Efficient induction of mouse immune responses to hepatitis C virus by viral core protein-carrying attenuated Salmonella typhimurium. Viral Immunol 2007, 20(September (3)):469-478.
21. Johansson D.X., Viosset C., Tarr A.W., Aung M., Ball J.K., Dubuisson J., et al. Human combinatorial libraries yield rare antibodies that broadly neutralize hepatitis C virus. Proc Natl Acad Sci U S A 2007, 104(October (41)):16269-16274.
22. Law M., Maruyama T., Lewis J., Giang E., Tarr A.W., Stamataki Z., et al. Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge. Nat Med 2008, 14(January (1)):25-27.
23. Broering T.J., Garrity K.A., Boatright N.K., Sloan S.E., Sandor F., Thomas W.D., et al. Identification and characterization of broadly neutralizing human monoclonal antibodies directed against the E2 envelope glycoprotein of hepatitis C virus. J Virol 2009, 83(December (23)):12473-12482.
24. Zeisel M.B., Fafi-Kremer S., Fofana I., Barth H., Stoll-Keller F., Doffoel M., et al. Neutralizing antibodies in hepatitis C virus infection. World J Gastroenterol 2007, 13(September (36)):4824-4830.
25. Keck Z.Y., Machida K., Lai M.M., Ball J.K., Patel A.H., Foung S.K. Therapeutic control of hepatitis C virus: the role of neutralizing monoclonal antibodies. Curr Top Microbiol Immunol 2008, 317:1-38.
26. Stoll-Keller F., Barth H., Fafi-Kremer S., Zeisel M.B., Baumert T.F. Development of hepatitis C virus vaccines: challenges and progress. Expert Rev Vaccines 2009, 8(March (3)):333-345.
27. Dubuisson J. Folding, assembly and subcellular localization of hepatitis C virus glycoproteins. Curr Top Microbiol Immunol 2000, 242:135-148.
28. Op De Beeck A., Cocquerel L., Dubuisson J. Biogenesis of hepatitis C virus envelope glycoproteins. J Gen Virol 2001, 82(November (Pt 11)):2589-2595.
29. Burlone M.E., Budkowska A. Hepatitis C virus cell entry: role of lipoproteins and cellular receptors. J Gen Virol 2009, 90(May (Pt 5)):1055-1070.
30. Lavillette D., Pécheur E.I., Donot P., Fresquet J., Molle J., Corbau R., et al. Characterization of fusion determinants points to the involvement of three discrete regions of both E1 and E2 glycoproteins in the membrane fusion process of hepatitis C. J Virol 2007, 81(16):8752-8765.
31. Paglia P., Medina E., Arioli I., Guzman C.A., Colombo M.P. Gene transfer in dendritic cells, induced by oral DNA vaccination with Salmonella typhimurium, results in protective immunity against a murine fibrosarcoma. Blood 1998, 92(November (9)):3172-3176.
32. Mollenkopf H.J., Groine-Triebkorn D., Andersen P., Hess J., Kaufmann S.H. Protective efficacy against tuberculosis of ESAT-6 secreted by a live Salmonella typhimurium vaccine carrier strain and expressed by naked DNA. Vaccine 2001, 19(July (28-29)):4028-4035.
33. Koesling J., Lucas B., Develioglou L., Aebischer T., Meyer T.F. Vaccination of mice with live recombinant Salmonella typhimurium aroA against H. pylori: parameters associated with prophylactic and therapeutic vaccine efficacy. Vaccine 2001, 20(November (3-4)):413-420.
34. Xie C., He J.S., Zhang M., Xue S.L., Wu Q., Ding X.D., et al. Oral respiratory syncytial virus (RSV) DNA vaccine expressing RSV F protein delivered by attenuated Salmonella typhimurium. Hum Gene Ther 2007, 18(August (8)):746-752.
35. Zhao P., Ke S., Wang H.W., Qian F., Qi Z.T. Enhancement by an in vivo-activated promoter of immunogenicity of recombinant attenuated Salmonella typhimurium expressing hepatitis C virus core antigen. Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai) 2003, 35(March (3)):266-270.
36. Yagnik A.T., Lahm A., Meola A., Roccasecca R.M., Ercole B.B., Nicosia A., et al. A model for the hepatitis C virus envelope glycoprotein E2. Proteins 2000, 40(August (3)):355-366.
37. Bartosch B., Dubuisson J., Cosset F.L. Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes. J Exp Med 2003, 197(March (5)):633-642.
38. Hsu M., Zhang J., Flint M., Logvinoff C., Cheng-Mayer C., Rice C.M., et al. Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles. Proc Natl Acad Sci U S A 2003, 100(June (12)):7271-7276.
39. Stamataki Z., Coates S., Evans M.J., Wininger M., Crawford K., Dong C., et al. Hepatitis C virus envelope glycoprotein immunization of rodents elicits cross-reactive neutralizing antibodies. Vaccine 2007, 25(November (45)):7773-7784.
40. Zhang P., Wu C.G., Mihalik K., Virata-Theimer M.L., Yu M.Y., Alter H.J., et al. Hepatitis C virus epitope-specific neutralizing antibodies in Igs prepared from human plasma. Proc Natl Acad Sci U S A 2007, 104(May (20)):8449-8454.
41. Mondelli M.U., Cerino A., Meola A., Nicosia A. Variability or conservation of hepatitis C virus hypervariable region 1? Implications for immune responses. J Biosci 2003, 28(April (3)):305-310.
42. Mondelli M.U., Cerino A., Segagni L., Meola A., Cividini A., Silini E., et al. Hypervariable region 1 of hepatitis C virus: immunological decoy or biologically relevant domain?. Antiviral Res 2001, 52(November (2)):153-159.
43. Owsianka A., Tarr A.W., Juttla V.S., Lavillette D., Bartosch B., Cosset F.L., et al. Monoclonal antibody AP33 defines a broadly neutralizing epitope on the hepatitis C virus E2 envelope glycoprotein. J Virol 2005, 79(September (17)):11095-11104.
44. Tarr A.W., Owsianka A.M., Timms J.M., McClure C.P., Brown R.J., Hickling T.P., et al. Characterization of the hepatitis C virus E2 epitope defined by the broadly neutralizing monoclonal antibody AP33. Hepatology 2006, 43(March (3)):592-601.
45. Geissler M., Gesien A., Tokushige K., Wands J.R. Enhancement of cellular and humoral immune responses to hepatitis C virus core protein using DNA-based vaccines augmented with cytokine-expressing plasmids. J Immunol 1997, 158(February (3)):1231-1237.
46. Hu G.J., Wang R.Y., Han D.S., Alter H.J., Shih J.W. Characterization of the humoral and cellular immune responses against hepatitis C virus core induced by DNA-based immunization. Vaccine 1999, 17(August (23-24)):3160-3170.
47. Isaguliants M.G., Petrakova N.V., Kashuba E.V., Suzdaltzeva Y.G., Belikov S.V., Mokhonov V.V., et al. Immunization with hepatitis C virus core gene triggers potent T-cell response, but affects CD4+ T-cells. Vaccine 2004, 22(April (13-14)):1656-1665.
48. Encke J., zu Putlitz J., Stremmel W., Wands J.R. CpG immuno-stimulatory motifs enhance humoral immune responses against hepatitis C virus core protein after DNA-based immunization. Arch Virol 2003, 148(March (3)):435-448.
49. Wilson M., Seymour R., Henderson B. Bacterial perturbation of cytokine networks. Infect Immun 1998, 66(June (6)):2401-2409.
50. Xu F., Ulmer J.B. Attenuated salmonella and Shigella as carriers for DNA vaccines. J Drug Target 2003, 11(8-10):481-488.
51. Xiang R., Luo Y., Niethammer A.G., Reisfeld R.A. Oral DNA vaccines target the tumor vasculature and microenvironment and suppress tumor growth and metastasis. Immunol Rev 2008, 222(April):117-128.
52. Dunstan S.J., Simmons C.P., Strugnell R.A. Use of in vivo-regulated promoters to deliver antigens from attenuated salmonella enterica var. Typhimurium. Infect Immun 1999, 67(October (10)):5133-5141.
53. Garcia Vescovi E., Soncini F.C., Groisman E.A. Mg2+ as an extracellular signal: environmental regulation of Salmonella virulence. Cell 1996, 84(January (1)):165-174.
54. Youn J.W., Park S.H., Lavillette D., Cosset F.L., Yang S.H., Lee C.G., et al. Sustained E2 antibody response correlates with reduced peak viremia after hepatitis C virus infection in the chimpanzee. Hepatology 2005, 42(December (6)):1429-1436.
55. Lavillette D., Morice Y., Germanidis G., Donot P., Soulier A., Pagkalos E., et al. Human serum facilitates hepatitis C virus infection, and neutralizing responses inversely correlate with viral replication kinetics at the acute phase of hepatitis C virus infection. J Virol 2005, 79(May (10)):6023-6034.
56. Manzin A., Solforosi L., Petrelli E., Macarri G., Tosone G., Piazza M., et al. Evolution of hypervariable region 1 of hepatitis C virus in primary infection. J Virol 1998, 72(July (7)):6271-6276.
57. Bartosch B., Verney G., Dreux M., Donot P., Morice Y., Penin F., et al. An interplay between hypervariable region 1 of the hepatitis C virus E2 glycoprotein, the scavenger receptor BI, and high-density lipoprotein promotes both enhancement of infection and protection against neutralizing antibodies. J Virol 2005, 79(July (13)):8217-8229.
58. Bankwitz D., Steinmann E., Bitzegeio J., Ciesek S., Friesland M., Herrmann E., et al. Hepatitis C virus hypervariable region 1 modulates receptor interactions, conceals the CD81 binding site, and protects conserved neutralizing epitopes. J Virol 2010, 84(June (11)):5751-5763.
59. Tarr A.W., Owsianka A.M., Jayaraj D., Brown R.J., Hickling T.P., Irving W.L., et al. Determination of the human antibody response to the epitope defined by the hepatitis C virus-neutralizing monoclonal antibody AP33. J Gen Virol 2007, 88(November (Pt 11)):2991-3001.